148 related articles for article (PubMed ID: 19157633)
1. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
[TBL] [Abstract][Full Text] [Related]
2. The XRCC1 and TP53 gene polymorphisms are associated with advanced-stage disease and early distant metastasis at diagnosis in non-small cell lung cancer.
Karaağaç M; Geredeli Ç; Yıldırım MS; Altınok T; Dede İ; İnal A; Zamani AG; Kaya B; Demirkazık A; Artaç M
J Cancer Res Ther; 2023; 19(5):1248-1254. PubMed ID: 37787291
[TBL] [Abstract][Full Text] [Related]
3. The association of XRCC1 gene single nucleotide polymorphisms with response to neoadjuvant chemotherapy in locally advanced cervical carcinoma.
Cheng XD; Lu WG; Ye F; Wan XY; Xie X
J Exp Clin Cancer Res; 2009 Jun; 28(1):91. PubMed ID: 19563645
[TBL] [Abstract][Full Text] [Related]
4. ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer.
Warnecke-Eberz U; Vallböhmer D; Alakus H; Kütting F; Lurje G; Bollschweiler E; Wienand-Dorweiler A; Drebber U; Hölscher AH; Metzger R
J Gastrointest Surg; 2009 Aug; 13(8):1411-21. PubMed ID: 19421825
[TBL] [Abstract][Full Text] [Related]
5. Association between Genetic Variants and Peripheral Neuropathy in Patients with NSCLC Treated with First-Line Platinum-Based Therapy.
de Jong C; Herder GJM; van Haarlem SWA; van der Meer FS; van Lindert ASR; Ten Heuvel A; Brouwer J; Egberts TCG; Deneer VHM
Genes (Basel); 2023 Jan; 14(1):. PubMed ID: 36672910
[TBL] [Abstract][Full Text] [Related]
6. Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.
Stewart DJ
Crit Rev Oncol Hematol; 2010 Sep; 75(3):173-234. PubMed ID: 20047843
[TBL] [Abstract][Full Text] [Related]
7. Association between the ERCC5 Asp1104His polymorphism and cancer risk: a meta-analysis.
Zhu ML; Wang M; Cao ZG; He J; Shi TY; Xia KQ; Qiu LX; Wei QY
PLoS One; 2012; 7(7):e36293. PubMed ID: 22815677
[TBL] [Abstract][Full Text] [Related]
8. [cDNA microarray technique on screening multi-drug resistance-related genes of human non-small cell lung cancer].
Liu M; Li C; Yan A; Cai L
Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):322-5. PubMed ID: 20677558
[TBL] [Abstract][Full Text] [Related]
9. Role of rs873601 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy.
Zou T; Liu JY; Qin Q; Guo J; Zhou WZ; Li XP; Zhou HH; Chen J; Liu ZQ
Biomedicines; 2023 Nov; 11(12):. PubMed ID: 38137354
[TBL] [Abstract][Full Text] [Related]
10. Pipeline design to identify key features and classify the chemotherapy response on lung cancer patients using large-scale genetic data.
Valdés MG; Galván-Femenía I; Ripoll VR; Duran X; Yokota J; Gavaldà R; Rafael-Palou X; de Cid R
BMC Syst Biol; 2018 Nov; 12(Suppl 5):97. PubMed ID: 30458782
[TBL] [Abstract][Full Text] [Related]
11. RAD52 variants predict platinum resistance and prognosis of cervical cancer.
Shi TY; Yang G; Tu XY; Yang JM; Qian J; Wu XH; Zhou XY; Cheng X; Wei Q
PLoS One; 2012; 7(11):e50461. PubMed ID: 23209746
[TBL] [Abstract][Full Text] [Related]
12. Genetic Polymorphisms and the Efficacy of Platinum-Based Chemotherapy: Review.
Afifah NN; Diantini A; Intania R; Abdulah R; Barliana MI
Pharmgenomics Pers Med; 2020; 13():427-444. PubMed ID: 33116759
[TBL] [Abstract][Full Text] [Related]
13. Genetic Variants Associated With Response to Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer Patients: A Field Synopsis and Meta-Analysis.
Sito H; Sharzehan MAK; Islam MA; Tan SC
Br J Biomed Sci; 2024; 81():11835. PubMed ID: 38450253
[No Abstract] [Full Text] [Related]
14. Genetic polymorphisms as potential pharmacogenetic biomarkers for platinum-based chemotherapy in non-small cell lung cancer.
Sito H; Tan SC
Mol Biol Rep; 2024 Jan; 51(1):102. PubMed ID: 38217759
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic Association between
Zhang N; Ouyang Y; Chang J; Liu P; Tian X; Yu J
Biomed Res Int; 2020; 2020():3520764. PubMed ID: 33150172
[TBL] [Abstract][Full Text] [Related]
16. NSD1 mutations by HPV status in head and neck cancer: differences in survival and response to DNA-damaging agents.
Pan C; Izreig S; Yarbrough WG; Issaeva N
Cancers Head Neck; 2019; 4():3. PubMed ID: 31321084
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and prognostic values of the mRNA expression of excision repair cross-complementation enzymes in hepatitis B virus-related hepatocellular carcinoma.
Yang L; Xu M; Cui CB; Wei PH; Wu SZ; Cen ZJ; Meng XX; Huang QG; Xie ZC
Cancer Manag Res; 2018; 10():5313-5328. PubMed ID: 30464628
[TBL] [Abstract][Full Text] [Related]
18.
Liu ZQ; Chen GG; Sun RL; Chen C; Lu MY; Guan LF; Chi XL; Jian YQ; Zhu X; Liu RQ; Cai BY; Chen FF; Liu B
Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30139812
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
